Current Controversies in Oncology and Current Insights in Oncology articles provide a forum for the exchange of views on topical issues in the field of oncology. The opinions expressed are those of the authors alone. They do not necessarily reflect the views of the Editor or ASCO.
Jul 14, 2017
In this excerpt from the 2017 ASCO Educational Book, four experts from different fields offer perspectives on how to address the challenging question of cost of care.
May 02, 2017
Dr. George D. Demetri and Dr. Jaap Verweij debate whether physicians should use olaratumab as a new standard of care for patients with metastatic STS today, or wait until the phase III trial results are available.
Mar 02, 2017
In this excerpt from the 2016 ASCO Educational Book, the authors describe the development of soluble factors, such as serum proteins, as biomarkers in immunotherapy.
Dec 22, 2016
Dr. Gary W. Falk and Drs. Christopher H. Blevins and Prasad G. Iyer debate whether or not to screen patients for Barrett's esophagus. Introduction by Dr. Srinadh Komanduri.
Oct 20, 2016
Dr. Filipa Lynce and Dr. Claudine Isaacs discuss the pros and cons of single/limited gene testing versus multigene panels for identifying hereditary susceptibility to cancer in this excerpt from the 2016 ASCO Educational Book.
Adjuvant Treatment for R0, Tumor-Free Rectal Carcinoma Following Neoadjuvant Treatment: The Case for and Against
Aug 10, 2016
Drs. Bruce D. Minsky and Bengt Glimelius debate the use of adjuvant treatment for R0, tumor-free rectal carcinoma following neoadjuvant treatment, with an introduction by Dr. Bertram Wiedenmann.
Jun 29, 2016
Drs. David P. Ryan and Edward A. Levine debate the use of CRS/HIPEC in patients with peritoneal metastases from colorectal cancer. Introduction by Dr. Paul H. Sugarbaker.
Apr 26, 2016
Americans are not dying well. Jeanie M. Youngwerth, MD, and D. Ross Camidge, MD, PhD, discuss the use of cancer therapy in tandem with palliative care in this article, with an introduction by Daniel W. Bowles, MD.
Feb 23, 2016
Dr. Robert Rifkin and Dr. Huub Schellekens provide an excellent discussion of the opportunities presented by biosimilar agents and several of the misconceptions or myths that have arisen around their development and use in oncology practice.
Dec 14, 2015
A powerful tool for genomic characterization of cancer is next-generation sequencing. There is an increasing interest in the role of NGS in improving the management of metastatic renal cell carcinoma.